Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Profit After Tax (2017 - 2026)

Kiniksa Pharmaceuticals International filings provide 6 years of Profit After Tax readings, the most recent being $22.6 million for Q1 2026.

  • On a quarterly basis, Profit After Tax rose 164.57% to $22.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $73.1 million, a 531.02% increase, with the full-year FY2025 number at $59.0 million, up 236.61% from a year prior.
  • Profit After Tax hit $22.6 million in Q1 2026 for Kiniksa Pharmaceuticals International, up from $14.2 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of $224.1 million in Q3 2022 to a low of -$25.2 million in Q1 2022.
  • Median Profit After Tax over the past 5 years was $4.5 million (2022), compared with a mean of $13.9 million.
  • Biggest five-year swings in Profit After Tax: surged 833.67% in 2022 and later tumbled 135.22% in 2024.
  • Kiniksa Pharmaceuticals International's Profit After Tax stood at $4.5 million in 2022, then surged by 465.73% to $25.2 million in 2023, then crashed by 135.22% to -$8.9 million in 2024, then surged by 259.75% to $14.2 million in 2025, then skyrocketed by 59.11% to $22.6 million in 2026.
  • The last three reported values for Profit After Tax were $22.6 million (Q1 2026), $14.2 million (Q4 2025), and $18.4 million (Q3 2025) per Business Quant data.